Compare AbCellera Biologics Inc (ABCL) vs PAGSEG Inc (PAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs PAGSEG Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while PAGSEG Inc trades at $8.71 (market cap $2.49B). The key difference: AbCellera Biologics Inc and PAGSEG Inc are close in size by market cap, and PAGSEG Inc pays a 11.69% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PAGS | |
|---|---|---|
Market Cap | $2.35B | $2.49B |
Sector | Health | Technology |
52-Week High | $8.12 | $12.00 |
52-Week Low | $2.78 | $7.75 |
Enterprise Value | $1.99B | $10.12B |
Dividend Yield | — | 11.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
PAGS trades at $8.93, down 2.08% for the day, with a bearish technical signal from moving averages. The stock shows strong value fundamentals with a P/E of 6.32 and P/B of 0.89. Recent earnings were mixed, missing in Q1 2026 but beating in Q4 2025. The company maintains solid profitability with a 10.4% net income margin and generated positive net cash flow of $930 million in 2025. A dividend of $0.26 per share is scheduled for payment on June 1, 2026.
The investment outlook is supported by deep valuation discounts and analyst optimism, with 15 buy ratings. However, near-term headwinds include flat payment volume growth and pressure from Brazilian interest rates. The primary risk remains macroeconomic sensitivity in Brazil, while the opportunity lies in potential expansion of banking and credit operations driving future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
